logo

HAUSA

Abu Mafi Muhimmanci Shi Ne Yadda Ake Iya Samun Alluran Rigakafin COVID-19

2021-05-10 20:54:39 CRI

Abu Mafi Muhimmanci Shi Ne Yadda Ake Iya Samun Alluran Rigakafin COVID-19_fororder_allura-1

A kwanakin baya gwamnatin kasar Amurka ta sanar da goyon bayan kiran da aka yi na dakatar da ‘yancin mallakar fasahar kera alluran rigakafin cutar COVID-19. Daga baya a yayin wani taron manema labaru da ma’aikatar harkokin wajen kasar Sin ta kira, wani dan jaridar kasar waje ya yi tambaya kan ra’ayin kasar Sin dangane da batun. Yayin da yake amsa tambayar, kakakin ma’aikatar harkokin wajen kasar Sin Wang Wenbin ya ce, kasar Sin ta fi mai da hankali kan yadda ‘yan kasashe daban daban suke iya samun alluran rigakafin.

Kafin haka, yadda kasar Amurka take kokarin mai da kanta tamkar ta fi sauran kasashe, a lokacin da ake rarraba alluran rigakafi, da hana fitar da sinadaran da ake bukata domin hada alluran rigakafin cutar COVID-19, ya sa kasar ta gamu da suka sosai daga al’ummar duniya. Yanzu bisa la’akari da yadda ake samun sassauci a cikin gidanta a fannin fama da annobar COVID-19, da gudanar da aikin yin alluran rigakafin cutar yadda ake bukata, gwamnatin kasar Amurka ta sanar da niyyarta ta dakatar da ‘yancin mallakar fasahar hada alluran rigakafin cutar COVID-19, don nuna cewa, kasar na “jagorantar” ayyukan dakile annobar COVID-19 a duniya. Sai dai abin tambaya a nan shi ne: shin wannan manufa ta Amurka tana da ma’ana?

Da farko, ya kamata mu lura da cewa, dakatar da ikon mallakar fasahar hada alluran rigakafin COVID-19 wani aiki ne mai wuya sosai, domin ya shafi moriya ta kasashe daban daban. Ko a cikin gidan kasar Amurka ma, sai majalissun dokokin kasar sun tantance wannan manufa sosai, kafin a yanke shawara a kai. Sa’an nan, kasashe daban daban su ma za su tattauna batun, bisa tsarin kungiyar ciniki ta duniya WTO. Ka’idojin kungiyar sun kayyade cewa, dole a samu amincewar dukkan mambobinta 164, kafin a iya zartas da wani kuduri. Sai dai, kungiyar tarayyar kasashen Turai EU ta riga ta zartas da niyyar dakatar da aikin soke ‘yancin mallakar fasahar hada rigakafin cutar COVID-19 a ranar 8 ga watan da muke ciki. Hakan na nufin cewa, za a dade ana fuskantar ce-ce-ku-ce a cikin kungiyar WTO dangane da lamarin.

Ban da wannan kuma, dakatar da ‘yancin mallakar fasaha ba lalle ne ya taimakawa aikin samar da alluran rigakafin COVID-19 ba. Aikin samar da alluran rigakafin ya shafi fasahohi ne na ci gaba, da na’urorin hada magunguna na musamman, don haka ba dukkan kasashe ne za su iya fara samar da alluran rigakafin nan take ba. Za a ci gaba da dogaro kan wasu manyan kamfanonin hada magunguna wajen biyan bukatun kasashe daban daban na samun dimbin alluran rigakafin cutar COVID-19. Sai dai dakatar da ‘yancin mallakar fasahar hada rigakafin, zai haddasa asara ga wadannan kamfanoni, da hana su samar da karin alluran rigakafin, da gudanar da nazari a kansu. Sanar da niyyarta ta dakatar da ‘yancin mallakar fasahar ke da wuya, sai manyan kamfanonin hada alluran rigakafin cutar COVID-19 guda 3, wato Moderna, da Johnson & Johnson, da BioNTech, sun yi asarar kudin hannayen jarinsu da ya kai dalar Amurka biliyan 7.7.

Abu Mafi Muhimmanci Shi Ne Yadda Ake Iya Samun Alluran Rigakafin COVID-19_fororder_allura-2

Ganin yadda gabatar da niyyar dakatar da ‘yancin mallakar fasahar hada alluran rigakacin cutar COVID-19 ba zai taimakawa aikin samar da alluran ba, ya sa kasar Sin ta fi mai da hankali kan tabbatar da cewa, za a iya samun alluran rigakafin, tare da yin amfani da su wajen dakile cutar COVID-19. Sai dai ta yaya kasar Sin ta tabbatar da hakan?

Da farko, ta yi kokarin tabbatar da ingancin alluran rigakafin COVID-19 da ta samar.

A ranar 7 ga wata, hukumar WHO ta sanya allurar rigakacin cutar COVID-19 da kamfanin Sinopharm na kasar Sin ya samar cikin jerin alluran rigakafin COVID-19 da za a rika amfani da su na gaggawa, inda ta nuna amincewarta kan inganci da tsaro na allurar, da yadda take da amfani ga aikin kawar da cutar COVID-19. Sa’an nan, allurar rigakafin da kamfanin Sinovac na kasar Sin ya samar, ita ma ta janyo hankalin al’ummar duniya bisa wani gwajin da aka yi a garin Serrana na kasar Brazil. Wani rahoton da jaridar Wall Street Journal ta kasar Amurka ta fitar, ya nuna cewa, bayan an yi alluran rigakafin cutar COVID-19 na kamfanin Sinovac kan yawancin mutanen garin, yawan mutanen garin da suka kamu da cutar COVID-19 ya ragu da kashi 75%, idan an kwatanta da yanayin da ake ciki a watan Maris. Dukkan wadannan batutuwa shaidu ne na ingancin alluran rigakafin cutar COVID-19 na kasar Sin.

Na biyu shi ne, kasar Sin ta yi kokarin samar da karin alluran rigakafin cutar COVID-19 don biyan bukatun al’ummomin kasashe daban daban.

Wani jami’i mai kula da aikin samar da alluran rigakafin cutar COVID-19 na kasar Sin ya bayyana a kwanan baya cewa, yawan alluran rigakafin da kasar Sin za ta samar a bana, zai wuce biliyan 3, kana kasar za ta iya samar da alluran rigakafin kusan biliyan 5 a shekara. Hakan na nufin cewa, alluran rigakafin da kasar Sin ta samar cikin shekaru 2, za su biya bukatar baiwa duk wani mutum na duniyarmu allura guda daya. Ban da wannan kuma, a ranar 6 ga watan da muke ciki, an kammala gina rufin wani sabon dakin hada alluran rigakafin cutar COVID-19 mafi girma a duniya na kamfanin Sinopharm na kasar Sin dake birnin Beijing. Bayanai na cewa, bayan an fara yin amfani da dakin, yawan alluran rigakafin da kamfanin zai samar a duk shekara, zai kai biliyan 3. Hakan zai kara karfin kasar Sin na samar da dimbin alluran rigakafin cutar COVID-19 cikin sauri.

Na uku, kasar Sin tana kokarin samar da alluran rigakafin COVID-19 wadanda ake iya adana da jigilarsu cikin sauki.

Yadda ake rashin kayayyakin adana da jigilar alluran rigakafin cutar COVID-19 a wasu kasashe masu tasowa, ya sa suke fuskantar matsalar rarraba alluran. Misali, a kasar jamhuriyar Congo, an fuskanci matsalar amfani da wasu alluran rigakafin cutar COVID-19 na AstraZeneca, sakamakon kasa jigilarsu. Abin da ya sa ta mika yawancin alluran ga sauran kasashe makwabtanta. Hakika yayin da ake amfani da wasu alluran rigakafin cutar COVID-19 da wasu kasashe masu ci gaban tattalin arziki suka samar, a kan gamu da matsalar wurin adana da jigilarsu. Misali, alluran rigakafin da kamfnain Pfizer na kasar Amurka ya samar na bukatar a ajiye su cikin wani yanayin zafi da ya kai tsakanin digrin Celcius 80 zuwa 60 kasa da sifiri. Wannan ya nuna cewa, dole ne a ajiye su cikin wasu na’urori masu inganci, wadanda yawancin kasashe masu tasowa ba su da su. Sai dai a nasu bangare, alluran rigakafin da kasar Sin ta samar, dukkansu ana iya ajiye su cikin yanayin mai zafin digri 2 zuwa 8. Hakan zai samar da sauki sosai ga aikin adana da jigilarsu.

Kana abu na karshe, kuma wanda ya fi muhimmanci, shi ne kasar Sin tana da cikakkiyar niyyar taimakawa sauran kasashe wajen dakile cutar COVID-19.

A halin yanzu, saurin gudanar aikin yi wa al’umma allurar rigakafin cutar COVID-19 a kasashe masu sukuni ya ninka na kasashe marasa karfin tattalin arziki har sau 25, hakan ya nuna yadda ake fama da matsalar rashin daidaito a fannin raba alluran rigakafin. Sabanin yadda kasar Amurka take kokarin boye alluran rigakafin a cikin gida, da haramta fitar da sinadaran da ake bukata wajen hada alluran, kasar Sin ta yi alkawarin mai da allurar rigakafin cutar COVID-19 a matsayin “kaya na jama’ar duniya”, tun kafin ta kammala nazarin alluran rigakafi na ta. Don cika alkawarin da ta yi, kasar Sin ta samar da tallafi na alluran rigakacin cutar COVID-19 ga kasashe a kalla 80, da kungiyoyin kasa da kasa 3. Kana ya zuwa karshen watan Maris na bana, kasar Sin ta riga ta fitar da alluran rigakafin miliyan 115 zuwa wasu kasashe 43. Ban da wannan kuma, kamfanonin kasar Sin sun yi hadin gwiwa da wasu kasashen da suke cikin shawarar “Ziri Daya da Hanya Daya”, irinsu Indonesia, da Brazil, da Hadaddiyar Daular Larabawa ta UAE, da Malaysia, da Pakistan, da Turkiyya, wajen samar da alluran rigakafin cutar COVID-19 a wadannan kasashe.

Idan mun sake duba matakan da kasar Amurka ta dauka, inda ta canza daga “Amurka ita ce na farko” zuwa niyyar “dakatar da ‘yancin mallakar fasahar hada alluran rigakafi”, za mu fahimci cewa, nufinta shi ne nuna wata alamar “jagorantar” aikin dakile annoba a duniya, bayan da ta tabbatar da mallake alluran a cikin gidanta. Matakin da shi ma bai wuce wani yunkuri na siyasantar da alluran rigakafin cutar COVID-19 ba, inda kasar ke fakewa da maganar alluran rigakafi don tabbatar da moriyarta a fannin siyasa. Sai dai a wannan lokacin da kasar India, da sauran kasashe makwabtanta, ke fama da tsanantar yanayin annobar cutar COVID-19, lamarin da ke haifar da babbar barazana ga daukacin bil Adama, kasar Amurka na ci gaba da dagewa kan manufar nuna son kai, da wasu abubuwa marasa ma’ana. Hakan zubar da kima ne a matsayinta na babbar kasa. Hakika duniyarmu ba ta bukatar wani “mai jagorantar ayyuka”, wanda ya dora muhimmanci kan “nuna wata alama”, maimakon “daukar hakikanin mataki mai amfani”. (Bello Wang)

Bello